Aclarion Inc. (ACON) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Aclarion Inc. (ACON)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

0.10

-0.01 (-8.42%)

At close: Jan 14, 2025, 3:59 PM

0.10

0.10%

Pre-market Jan 15, 2025, 07:58 AM EST

undefined% (undefined)

Bid	0.1
Market Cap	2.21M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-2.4
PE Ratio (ttm)	-0.04
Forward PE	n/a
Analyst	Hold

Ask	0.1
Volume	4,678,993
Avg. Volume (20D)	6,842,893
Open	0.11
Previous Close	0.11
Day's Range	0.10 - 0.11
52-Week Range	0.10 - 3.85
Beta	undefined

About ACON

Aclarion, Inc., a healthcare technology company, develops software application for magnetic resonance spectroscopy (MRS) in the United States. It offers NOCISCAN-LS Post-Processor suite comprising NOCICALC-LS that receives and processes the acquired disc MRS data to calculate levels of degenerative pain biomarkers; and NOCIGRAM-LS, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclari...

[Show more]

Industry Medical - Healthcare Information Services

Sector Healthcare

IPO Date Apr 22, 2022

Employees 4

Stock Exchange NASDAQ

Ticker Symbol ACON

Website https://www.aclarion.com

Analyst Forecast

According to 2 analyst ratings, the average rating for ACON stock is "Hold." The 12-month stock price forecast is $1.3, which is an increase of 1258.41% from the latest price.

Buy 50.00%

Hold 50.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Aclarion Inc. is scheduled to release its earnings on Mar 27, 2025, after market closes.
Analysts project revenue of $22.50K, reflecting a 63.08% YoY growth and earnings per share of -0.17, making a 183.33% increase YoY.

Why Price Moved

6 months ago · Source

+1.75%

ACON: Aclarion shares are trading higher after the... Unlock content with Pro Subscription

8 months ago · Source

+36.35%

Aclarion shares are trading higher after the company announced that its Nociscan solution will be used in the upcoming LIFEHAB trial evaluating the diagnosis and treatment of chronic low back pain.

News

3 weeks ago · zacks.com

Aclarion (ACON) Upgraded to Buy: Here's What You Should Know

Aclarion (ACON) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.